- Ongoing, recruitingTherapeutic exploratory (Phase II)
HLH-JAK - Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trial
This study is testing a new medicine called Itacitinib for adults with a non-severe form of a rare immune condition called HLH. Researchers want to see if it improves symptoms within 15 days, helping to calm down the overactive immune system.
For: Adults patients having non severe HLHFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
This study offers ongoing treatment with a medicine called Itacitinib for adults who have already participated in earlier studies of this drug. It primarily monitors for any side effects and ensures continued access to the medication for conditions like myelofibrosis or chronic graft-versus-host disease.
For: Myelofibrosis · postlung transplant (BOS) · chronic graft-versus-host diseaseItaly · Spain · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial
This study, called SCLERITA, is testing a new medicine called itacitinib for adults with a condition called systemic sclerosis (scleroderma). We want to see if it's safe and helps improve the skin and overall health after about a year, compared to a dummy pill.
For: Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screeningFrance